



PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/716,095
	Filing Date	November 18, 2003
	First Named Inventor	Kacmarek
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21489

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time/Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks Form 1449, References</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Eileen M. Ebel
Signature	
Date	February 20, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date February 20, 2004			
Typed or printed	Eileen M. Ebel		
Signature		Date	February 20, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) A. Kacmarek, E. Kopetzki, C. Schantz, S. Seeber Group:

Serial No. 10/716,095, filed November 18, 2003

Examiner:

For: METHODS FOR THE RECOMBINANT PRODUCTION OF ANTIFUSOGENIC
PEPTIDE

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 20, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

A Partial European Search Report from corresponding European application 02025618.6 which is dated September 10, 2003, is enclosed. Documents from the Search Report are cited herein as documents B1, B2, and C25.


Documents A1 – A8 listed on Form PTO-1449 are not enclosed because they are US Patents. Documents B1 – B7 and C1 – C34 are enclosed.

Serial No. 10/716,095
Filed: November 18, 2003

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before receipt of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due. If a fee is owing, please charge our deposit account 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37,316)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

138487



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Complete if Known

Application Number	10/716,095
Filing Date	November 18, 2003
First Name Inventor	Kacmarek
Group Art Unit	
Examiner Name	
Attorney Docket Number	21489

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5,464,933		Bolognesi, et al.	11-07-1995
	A2	5,656,480		Wild et al.	08-12-1997
	A3	6,013,263		Barney, et. al.	01-11-2000
	A4	6,017,536		Barney, et. al.	01-25-2000
	A5	6,020,459		Barney, et al.	02-01-2000
	A6	6,060,065		Barney, et al.	05-09-2000
	A7	6,093,794		Barney, et al.	07-25-2000
	A8	6,291,245		Kopetzki, et. al.	09-18-2001
	A9	5,543,363		Rulolph, et al	09-26-1995
	A10	5,635,371		Stout, et al.	06-03-1997
	A11	5,656,456		Stout, et al.	08-12-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO	00/69902		Conjuchem Inc.	11-23-2000	
	B2	WO	01/44286		Whitehead Institute for Biomedical Research	06-21-2001	
	B3	WO	02/103026		F. Hoffmann-La Roche AG	12-27-2002	
	B4	WO	96/19495		Duke University	06-27-1996	
	B5	WO	96/40191		Trimeris Inc.	12-19-1996	
	B6	WO	99/48513		Trimeris, Inc.	09/30/1999	
	B7	WO	99/59615		Trimeris Inc.	11-25-1999	
	B8	DE	30 34 045		Boehringer Mannheim GmbH	4/22/1982	
	B9	EP	424 990		Amgen Inc.	05/02/1991	
	B10	WO	92/01707		Bionebraska, Inc.	02/06/1992	
	B11	WO	94/01451		Bionebraska, Inc.	01/20/1994	
	B12	WO	95/03405		Bionebraska, Inc.	02/02/1995	
	B13	WO	00/31279		Micrologix Biotech Inc.	06/02/2000	
	B14	WO	94/04688		University of British Columbia	03/03/1994	
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/716,095
				Filing Date	November 18, 2003
				First Name Inventor	Kacmarek
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	3	Attorney Docket Number	21489

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item/(book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Andersson, L., et al., Biopolymers 55 (2000) 227-250	
	C2	Bradford, M., Analytical Biochemistry, 72, pp. 248-254 (1976)	
	C3	Cao, J., et. al., J. Virol. 67 (1993) 2747-2755	
	C4	Chan, D. C., et al., Proc. Natl. Acad. Sci. USA 95 (1998) 15613-15617	
	C5	Chan, D.C., et al, Cell 89 (1997) 263-273	
	C6	Chan, D.C., et al., Cell 93 (1998) 681-684	
	C7	Chen, C.H. et al., describe in J. Virol. 69 (1995) 3771-3777	
	C8	Dobeli et al., Protein Expression and Purification, 12, pp. 404-414 (1998)	
	C9	Gallaher, W.R., et al., Aids Res. Hum. Retrovirus 5 (1989) 431-440	
	C10	Goldberg et al., Maximizing Gene Expression, eds. Reznikoff and Gold, butterworks, Stoneham, MA, pp. 287-314 (1986)	
	C11	Hammarskjöld, M.-L., et al., Biochim. Biophys. Acta 989 (1989) 269-280	
	C12	Jones, J.H., J. Pept. Sci 6 (2000) 201-207	
	C13	Judice, J.K., et al., Proc. Natl. Acad. Sci. USA 94 (1997) 13426-13430	
	C14	Kilby, J.M., et al., Nature Medicine 4 (1998) 1302-1307	
	C15	Kopetzki, E., et al., Clin. Chem. 40 (1994) 688-704	
	C16	Lambert, D.M., et al., Proc. Natl. Acad. Sci. USA 93 (1996) 2186-2191	
	C17	Lawless, M.K., et al., Biochemistry 35 (1996) 13697-13708	
	C18	Lepage, P., et al., Analytical Biochemistry 213 (1993) 40-48	
	C19	Lilie, H., Curr. Opin. Biotechnol., 9, pp. 497-501 (1998)	
	C20	Maddon, P.J., et al., Cell 47 (1986) 333-348	
	C21	Malashkevich, V.N., et al., Proc. Natl. Acad. Sci. USA 95 (1998) 9134-9139	
	C22	McDougal, J.S., et al., Science 231 (1986) 382-385	
	C23	Mergler, M., et al., Tetrahedron Letters 29 (1988) 4005-4008	
	C24	Mergler, M., et al., Tetrahedron Letters 29 (1988) 4009-4021	
	C25	Misawa, S., et al., Biopolymers 51 (1999) 297-307	
	C26	Ningyi, L., et al., Gaojishu Tongxun 10 (2000) 28-31	
	C27	Rimsky, L.T., et al., J. Virol. 72 (1998) 986-993	
	C28	Polyak, et al., Protein Eng., 10, pp. 615-619 (1997)	
	C29	Root, M.J., et al., Science 291 (2001) 884-888	

	C30	Tan, K., et al., Proc. Natl. Acad. Sci. USA 94 (1997) 12303-12308	
	C31	Turner, B.G., and Summers, M.F., J. Mol. Biol. 285 (1999) 1-32	
	C32	Uhlen, M., and Moks, T., Methods Enzymol. 185 (1990) 129-143	
	C33	Van Heeke et al., Method Mol., Biol., 36, pp. 245-260 (1994)	
	C34	Weissenhorn, W., et al., Nature 387 (1997) 426-430	
	C35	Wild, C.T., et al., Proc. Natl. Acad. Sci. USA 91 (1994) 9770-9774	
Examiner Signature			DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

138481